itinai content

  • AI News
  • AI Sales
  • Apple AI
  • Biohacking
  • Clinical Trials
  • Compare
  • Computer Vision
  • DeepSense
  • farma
  • Instruments
  • Management
  • Marketing
  • Marktechpost
  • Open AI
  • resume
  • КП
  • This AI Paper Introduces VLM-R³: A Multimodal Framework for Region Recognition, Reasoning, and Refinement in Visual-Linguistic Tasks

    13 июня, 2025

    This AI Paper Introduces VLM-R³: A Multimodal Framework for Region Recognition, Reasoning, and Refinement in Visual-Linguistic Tasks Understanding the Target Audience The target audience for this paper primarily consists of AI researchers, data scientists, and business leaders in technology sectors focused on AI and machine learning applications. Their pain points include: Difficulty in achieving high… →

    AI News
  • Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial

    12 июня, 2025

    CONCLUSION: The PLD-based regimen for early-stage BC showed significantly lower rates of elevated hs-cTnT and grade 3-4 AEs with comparable efficacy to the doxorubicin-based regimen. (ClinicalTrials.gov Identifier: NCT03949634; IRB Approved: Ethics committee institutional review board of Shanghai Cancer Hospital, Fudan University’s (No. 1706173-19-1904B) and other center). →

    Clinical Trials
  • Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors)

    12 июня, 2025

    CONCLUSION: Topical netarsudil 0.02% once daily was well tolerated with fewer side effects and in reducing IOP than topical ripasudil 0.4% twice daily dosing in POAG patients. Netarsudil 0.02% once daily may be considered an important option for the IOP control in POAG. →

    Clinical Trials
  • Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single-Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double-Blind, Placebo-Controlled Study

    12 июня, 2025

    Allergic asthma, characterized by airborne allergen sensitivity and Th2 immune responses, is a common and increasing global health concern. Omalizumab, while effective, has limitations such as weight- and IgE-dependent dosing regimens. JYB1904, a recombinant anti-IgE humanized monoclonal antibody (IgG1 subtype), showed superior preclinical properties. We performed a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase Ia… →

    Clinical Trials
  • Central-boost Ablative Radiation Therapy for Solid Tumors: Study Protocol of a Single-arm, Phase II Trial (CBART)

    12 июня, 2025

    BackgroundThough stereotactic body radiation therapy (SBRT) has been widely used in advanced tumors, ablative doses may not be appropriate in the case of large tumors or those abutting to the gastrointestinal tracts, resulting in unfavorable outcomes. Therefore, partial irradiation with high doses to tumors have been investigated. In order to achieve a larger high dose… →

    Clinical Trials
  • Systematic evaluation of the effectiveness of Xuesaitong combined with nutraceutical drugs in the treatment of diabetic peripheral neuropathy

    12 июня, 2025

    This study aims to evaluate the effectiveness of combining Xuesaitong with nutraceutical drugs, including alpha-lipoic acid, B vitamins, and coenzyme Q10, in the treatment of diabetic peripheral neuropathy (DPN). A 12-week randomized controlled trial was conducted with 140 clinically diagnosed DPN patients, who were randomly assigned into two groups. The intervention group received Xuesaitong along… →

    Clinical Trials
  • An auxiliary role of deep neural network ophthalmic disease identification models in choosing medication treatment strategy

    12 июня, 2025

    To evaluated a Deep Neural Network (DNN)-based ophthalmic disease diagnosis framework in facilitating personalized medication treatment plans using a prospective, single-center, randomized controlled clinical trial design. 500 patients were randomly assigned to either a DNN-aided experimental group or a control group receiving standard physician-based treatment plans. The primary outcomes were medication selection accuracy, clinical efficacy… →

    Clinical Trials
  • Application and efficacy analysis of empowerment theory-based Pharmacological intervention in the rehabilitation of children with autism

    12 июня, 2025

    To explore the application and efficacy of a combined pharmacological and behavioral intervention in the rehabilitation of children with autism, emphasizing individualized treatment approaches. Ninety-six hospitalized children diagnosed with autism, aged 3-8 years, were randomly assigned to an experimental group or a control group. The control group received conventional interventions, including systematic language training, behavioral… →

    Clinical Trials
  • Herbal fumigation combined with vessels acupoint improves the prognosis and reduces inflammation in patients with dry eye disease: A retrospective study

    12 июня, 2025

    Dry eye disease (DED) is a prevalent condition often associated with inflammation and tear film dysfunction. Complementary treatments such as herbal fumigation and acupoint applications have shown promise in handling EDE. This study evaluates the combined efficacy of herbal fumigation and vessels acupoint in treating DED. A total of 123 DED patients were randomly assigned… →

    Clinical Trials
  • Meta AI Releases V-JEPA 2: Open-Source Self-Supervised World Models for Understanding, Prediction, and Planning

    12 июня, 2025

    «`html Meta AI Releases V-JEPA 2: Open-Source Self-Supervised World Models for Understanding, Prediction, and Planning Meta AI has introduced V-JEPA 2, a scalable open-source world model designed to learn from video at internet scale and enable robust visual understanding, future state prediction, and zero-shot planning. Building upon the joint-embedding predictive architecture (JEPA), V-JEPA 2 effectively… →

    AI News
Предыдущая страница
1 … 352 353 354 355 356 … 1 028
Следующая страница